Text Size

Reoperation Rates and Disease Costs for Primary Open-Angle Glaucoma Patients in the United States Treated with Incisional Glaucoma Surgery

Randy Craven E., Singh I.P., Yu T.M., Rhoten S., Sadruddin O.R., Sheybani A.


  • 2021
  • Ophthalmology Glaucoma
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Wilmer Eye Institute, John Hopkins University, Bethesda, MD, United States; The Eye Centers of Racine & Kenosha, Ltd, Racine, WI, United States; Life Sciences, Guidehouse, Inc, San Francisco, CA, United States; Global Medical Affairs, Santen USA, Emeryville, CA, United States; Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, MO, United States

Related Publications

Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.

Bacharach, Jason; McLaurin, Eugene B.; Silverstein, Steven; Amrane, Mourad; Garrigue, Jean-Sebastien; Ismail, Dahlia; Flynn, William J.; Catiolanze Phase 2 study group


Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022